Dr. Ou was formerly an employee of Theravance.
Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: A case study
Version of Record online: 29 AUG 2013
© 2013, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 53, Issue 11, pages 1112–1120, November 2013
How to Cite
Ou, Y. C., Lo, A., Lee, B., Liu, P., Kimura, K., Eary, C. and Hopkins, A. (2013), Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: A case study. Journal of Clinical Pharma, 53: 1112–1120. doi: 10.1002/jcph.157
- Issue online: 5 OCT 2013
- Version of Record online: 29 AUG 2013
- Accepted manuscript online: 2 AUG 2013 09:27AM EST
- Manuscript Accepted: 28 JUL 2013
- Manuscript Received: 15 FEB 2013
Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
|jcph157-sm-0001-SuppFig.docx||53K||Figure S1. Telavancin Case study: An example of dependence analysis provided by the SCE.|
Table S1. Roadmap for implementing Pharmacometrics analysis into the SCE.
Table S2. Required files for any single NONMEM run inside of the SCE.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.